Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Arthritogenic alphavirus vaccines: serogrouping versus cross-protection in mouse models
Author: Nguyen, W.
Nakayama, E.
Yan, K.
Tang, B.
Le, T.T.
Liu, L.
Cooper, T.H.
Hayball, J.D.
Faddy, H.M.
Warrilow, D.
Allcock, R.J.N.
Hobson-Peters, J.
Hall, R.A.
Rawle, D.J.
Lutzky, V.P.
Young, P.
Oliveira, N.M.
Hartel, G.
Howley, P.M.
Prow, N.A.
et al.
Citation: Vaccines, 2020; 8(2):209-1-209-26
Publisher: MDPI
Issue Date: 2020
ISSN: 2076-393X
Statement of
Wilson Nguyen, Eri Nakayama, Kexin Yan, Bing Tang, Thuy T. Le, Liang Liu, Tamara H. Cooper, John D. Hayball, Helen M. Faddy, David Warrilow, Richard J. N. Allcock, Jody Hobson-Peters, Roy A. Hall, Daniel J. Rawle, Viviana P. Lutzky, Paul Young, Nidia M. Oliveira, Gunter Hartel, Paul M. Howley, Natalie A. Prow, and Andreas Suhrbier
Abstract: Chikungunya virus (CHIKV), Ross River virus (RRV), o’nyong nyong virus (ONNV), Mayaro virus (MAYV) and Getah virus (GETV) represent arthritogenic alphaviruses belonging to the Semliki Forest virus antigenic complex. Antibodies raised against one of these viruses can cross-react with other serogroup members, suggesting that, for instance, a CHIKV vaccine (deemed commercially viable) might provide cross-protection against antigenically related alphaviruses. Herein we use human alphavirus isolates (including a new human RRV isolate) and wild-type mice to explore whether infection with one virus leads to cross-protection against viremia after challenge with other members of the antigenic complex. Persistently infected Rag1(-/-) mice were also used to assess the cross-protective capacity of convalescent CHIKV serum. We also assessed the ability of a recombinant poxvirus-based CHIKV vaccine and a commercially available formalin-fixed, whole-virus GETV vaccine to induce cross-protective responses. Although cross-protection and/or cross-reactivity were clearly evident, they were not universal and were often suboptimal. Even for the more closely related viruses (e.g., CHIKV and ONNV, or RRV and GETV), vaccine-mediated neutralization and/or protection against the intended homologous target was significantly more effective than cross-neutralization and/or cross-protection against the heterologous virus. Effective vaccine-mediated cross-protection would thus likely require a higher dose and/or more vaccinations, which is likely to be unattractive to regulators and vaccine manufacturers.
Keywords: Chikungunya virus; Ross River virus; Mayaro virus; o’nyong nyong virus; Getah virus
Rights: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
DOI: 10.3390/vaccines8020209
Grant ID:
Published version:
Appears in Collections:Aurora harvest 8
Microbiology and Immunology publications

Files in This Item:
File Description SizeFormat 
hdl_130953.pdfPublished Version6.43 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.